Physician profile

Daniel J Mchugh

Interventional Pain Medicine · Antioch, TN

NPI 1790766319

$6,253.17

in general payments reported to CMS, 2019-2025

44 companies · $1,235 in 2025

The $1,235 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,896.93

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbott Laboratories $784.35 2019-2025 Proclaim
Collegium Pharmaceutical, INC. $627.27 2019-2025 Belbuca, Xtampza
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $580.59 2019-2025 Relistor, Trulance
Lundbeck LLC $439.29 2020-2025 Vyepti
Pfizer INC. $362.15 2019-2024
Boston Scientific Corporation $329.18 2022-2025 Wavewriter Alpha Prime 16
Amgen INC. $251.60 2019-2023 Aimovig
Lilly USA, LLC $215.98 2019-2023 Reyvow, Emgality
Abbvie INC. $204.83 2021-2025
Novartis Pharmaceuticals Corporation $190.93 2019-2021
Vertex Pharmaceuticals Incorporated $175.42 2024-2025
Stryker Corporation $170.32 2025 Mild Device Kit
Scilex Pharmaceuticals INC. $165.56 2019-2025 Ztlido
Arbor Pharmaceuticals, INC. $164.69 2019-2021
Relievant Medsystems, INC. $123.68 2022
Show all 44 companies
CompanyGeneral paymentsYearsTop products
Spinefrontier, INC. $110.87 2024 Sijfuse
Teva Pharmaceuticals USA, INC. $107.04 2019-2022
Biodelivery Sciences International, INC. $100.12 2019-2021
Assertio Therapeutics, INC. $93.13 2019-2020
Pacira Therapeutics, INC. $91.88 2019-2021
Protega Pharmaceutials INC $87.94 2023-2025 Roxybond
Zyla Life Sciences, INC. $87.48 2019-2020
Ibsa Pharma INC. $73.08 2024-2025 Licart, Tirosint, Flector
Medtronic USA, INC. $70.19 2019
Biohaven Pharmaceutical Holding Company LTD. $65.78 2022
Pacira Pharmaceuticals Incorporated $53.41 2023-2025 Zilretta, Iovera
Daiichi Sankyo INC. $51.26 2019
Saluda Medical Americas, INC. $46.72 2025 Evoke
Medtronic, INC. $44.72 2024 Intellis Adaptivestim
Neuronetics, INC. $43.63 2019
Biohaven Pharmaceuticals, INC. $43.41 2021
Alnylam Pharmaceuticals INC. $37.86 2025 Givlaari
Allergan, INC. $33.33 2019
Mdd US Operations, LLC $30.78 2019-2020
Averitas Pharma INC. $29.30 2025 Qutenza
Kowa Pharmaceuticals America, INC. $26.07 2022-2023 Seglentis
Stimwave Technologies Incorporated $25.91 2019
Takeda Pharmaceuticals U.S.A., INC. $22.25 2019
Grt US Holding, INC. $17.93 2021
Hikma Pharmaceuticals USA $17.89 2022
Azurity Pharmaceuticals, INC. $17.84 2023 Horizant
Sentynl Therapeutics, INC. $13.32 2019
Horizon Therapeutics Plc $13.24 2022
Kaleo, INC. $10.95 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Daniel J Mchugh

$6,253.17

in general payments reported 2019-2025

Years
2019-2025
Top company
Abbott Laboratories
Context
The $1,235 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).

https://glasscript.com/doctor/171654/daniel-j-mchugh

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.